SavedAdd your journal

Journals / Gazi Medical Journal / 2003 / Cilt: 14 - Sayı: 4

Kronik plak psoriazisde topikal kalsipotriol ve metilprednizolon aseponatin klinik etkinlikleri

The clinical efficacy of topical calcipotriol and methylprednisolone aceponate in chronic plaque psoriasis

Esra ADIŞEN
Ayla GÜLEKON
Mehmet Ali GÜRER
Pages
175–179
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The difference was statistically significant (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To assess the clinical efficacy of calcipotriol and methylprednisolone aseponate ointments in the treatment of chronic plaque psoriasis.
📊
Key Findings & Data:Methods: This study involved 30 patients with stable and moderate severity chronic plaque psoriasis.
💡
Conclusion & Impact:The difference was statistically significant (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To assess the clinical efficacy of calcipotriol and methylprednisolone aseponate ointments in the treatment of chronic plaque psoriasis. Methods: This study involved 30 patients with stable and moderate severity chronic plaque psoriasis. The patients were divided into 2 treatment groups and administered calcipotriol ointment or methylprednisolone aseponate (MPA) ointment twice daily for 6 weeks. The Psoriasis Area and Severity Index (PASI) scoring system was used for the clinical evaluation. Pre-treatment and post-treatment PASI scores were compared. Results: In the calcipotriol group, the mean of pre-treatment PASI scores was 9.98 ± 1.76 and the mean of post-treatment PASI scores was 3.04 ± 0.88. The difference was statistically significant (p

Özet

Amaç: Kronik plak psoriazis tedavisinde kalsipotriol ve metilprednizolon aseponat pomadın klinik etkinliklerini karşılaştırmak. Materyal ve Metod: Çalışmaya stabil ve kronik plak psoriazisi bulunan 30 hasta alındı. Olgular iki gruba ayrılarak kalsipotriol pomad ve metilprednizolon aseponat (MPA) tedavilerini günde iki kez 6 hafta süreyle kullandılar. İlaçların klinik etkinlikleri Psoriasis Area and Severity Index (PASI) Skoru kullanılarak değerlendirildi. Tedavi öncesi ve sonrası PASI skorları istatistiksel olarak karşılaştırıldı. Bulgular: Kalsipotriol grubunda tedavi öncesi PASI skoru ortalaması 9.98 ± 1.76 ve tedavi sonrası 3.04 ± 0.88 idi ve aradaki fark istatistiksel olarak anlamlıydı (p

🔖

Cite This Article

ADIŞEN, E., GÜLEKON, A., GÜRER, M. A. (2022). Kronik plak psoriazisde topikal kalsipotriol ve metilprednizolon aseponatin klinik etkinlikleri. Gazi Medical Journal, Cilt: 14 - Sayı: 4, 175–179. https://ajindex.com/articles/520532

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Christophers E, Mrowietz U. Psoriasis. In. Freedberg IM, Eisen AZ, Wolf K, Austen KF, Goldsmith AL, Katz IS, Fitzpatrick TB (eds): Fitzpatrick's Dermatology in General Medicine. 5th ed. New York: McGraw-Hill Inc; 1999. p. 495-521
  2. Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC. Dermatology. Berlin: Springer; 2000
  3. Barker JNWN. Genetic aspects of psoriasis. Clin Exp Dermatol 2001; 26: 321-325
  4. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320
  5. Farber EM. The language of psoriasis. Int J Dermatol 1991; 30: 295-302
  6. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CME. What is the role of topical calcipotriol in the treatment of mild-to-moderate chronic plaque psoriasis? BMJ 2000; 320: 963-967
  7. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 1994; 131: 514-520
  8. Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001; 76: 943-949
  9. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris: Update and new strategies. Cutis 1999; 64: 315- 318
  10. Kecskes A, Mahn HD, Kuhlmann RK, Lange L. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal antiinflammatory activity. J Am Acad Dermatol 1993; 29: 576-580
  11. Kecskes A, Jahn P, Wendt H, Lange L, Kuhlmann RK. Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers. Eur J Clin Pharmacol 1992; 43: 157-159
  12. Tauber U, Matthes H. Percutaneous absorption of methylprednisolone aceponate after single and multiple dermal application as ointment in male volunteers. Arzneimittel-Forschung 1992; 42: 1122-1124
  13. Koo JYM. Current consensus and update on psoriasis therapy: A perspective from the US. J Dermatol 1999; 26: 723-733
  14. Federman DG, Froelich CW, Kirsner RS. Topical psoriasis therapy. Am Fam Physician 1999; 15: 14-19
  15. Linden KG, Weinstein GD. Psoriasis: Current perspectives with an emphasis on treatment. Am J Med 1999; 107: 595-605
  16. Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA. Biologie effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 36: 19-28
  17. Van de Kerkhof PCM, Green C, Hamberg KJ, Hutchinson PE, Jensen JK, Kidson P, Kragbella K, Larsen FG, Munro CS, Tillman DM. Safety and efficacy of combined high-dose treatment with calcipotriol ointment and sol